GLOW

weak data

Also seen as: GLOW Blend, GHK-Cu + BPC-157 + TB-500

The Dose Guy’s verdict

Sep 1, 2026
4 sources

GLOW is a blend of three peptides people already run individually: GHK-Cu for skin repair, BPC-157 for tissue healing, TB-500 for recovery. Each has a plausible mechanism. None has strong clinical data for skin quality specifically, and no trial exists on the combination. The case for GLOW is the case for stacking sensible parts and hoping the sum works. I like the logic, and the parts have earned their reputations individually. But the blend itself is a bet, and I want you to know the difference.

Would I take it?Sensible parts, untested as a blend.

What it is

A pre-mixed injectable blend of three peptides. GHK-Cu is a copper peptide that signals fibroblasts to build collagen and glycosaminoglycans, the scaffolding your skin loses with age. BPC-157 is a body-protection compound derived from gastric juice, used widely for joint and tendon recovery, now appearing in skin protocols. TB-500, synthetic thymosin beta-4, promotes cell migration and wound repair. The pitch is that the three together cover repair, protection, and turnover in one vial.

No standardized formulation exists. The ratios vary by supplier, and what you are buying is a vendor’s recipe, not a studied drug. That does not make the logic wrong. It means you are trusting the combination without blend-level evidence to back it.

What the research shows

No trial on GLOW as a blend. The receipts belong to the parts:

In a randomized vehicle-controlled diabetic ulcer trial, topical GHK-Cu gel produced 98.5% median plantar-ulcer area closure versus 60.8% with vehicle. GHK-Cu heals tissue. That much is real.Wound Repair Regen 1994 · GHK-Cu RCT

A systematic review of BPC-157 included 36 studies: 35 preclinical, one clinical. No clinical safety data in humans was found.2025 · BPC-157 systematic review · 36 studies

In 40 healthy volunteers, intravenous thymosin beta-4 at doses from 42 to 1,260 mg, given once and then daily for 14 days, caused no dose-limiting toxicity or serious adverse events.Ann N Y Acad Sci 2010 · TB-4 RCT · n=40

In 13 patients after carbon dioxide laser resurfacing, topical GHK-Cu did not significantly improve erythema resolution, wrinkles, or overall skin quality by objective assessment. The one cosmetic-specific GHK-Cu trial, and it missed.Arch Facial Plast Surg 2006 · RCT · n=13

No human trial of GLOW as a fixed combination of GHK-Cu, BPC-157, and TB-500 exists.as of Aug 2026

Realistic protocols

People run GLOW subcutaneously, typically two to three times a week, following the supplier’s dose per injection since no studied protocol exists. Most suppliers sell it as a pre-mixed vial you reconstitute and draw from. A typical cycle runs four to eight weeks, then a break before repeating.

The honest framing: you are running a blend whose components each have some basis, combined at ratios a supplier chose, for a duration nobody has studied. Community reports are consistent enough to take seriously: better skin texture, faster healing of minor cuts, a general “glow” that earned the product its name. But reports are not a trial.

If you want to know which component is pulling the weight, run them separately first. GHK-Cu for skin, BPC-157 for recovery, TB-500 for healing. You lose the one-vial convenience but gain the ability to know what works.

Standard1 vial draw, 2–3x/wkSub-q. Supplier vials vary in concentration, so follow the label. No studied dose exists to override it.

Cycle length4–8 weeksBreak before repeating. No data on continuous use of the blend.

Side effects

The blend carries whatever its parts carry, plus the uncertainty of mixing them:

anecdotalInjection-site redness or mild irritation, consistent with what subcutaneous peptide users report generally.

anecdotalMild nausea in the first few sessions, consistent with what BPC-157 users report on its own.

unknownNo safety data exists on the combination. Each component has some individual safety data, but three peptides in one syringe have not been studied together.